MX2022016019A - Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio. - Google Patents

Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio.

Info

Publication number
MX2022016019A
MX2022016019A MX2022016019A MX2022016019A MX2022016019A MX 2022016019 A MX2022016019 A MX 2022016019A MX 2022016019 A MX2022016019 A MX 2022016019A MX 2022016019 A MX2022016019 A MX 2022016019A MX 2022016019 A MX2022016019 A MX 2022016019A
Authority
MX
Mexico
Prior art keywords
compositions
methods
pompe disease
onset pompe
treating late
Prior art date
Application number
MX2022016019A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Finn
Haack Kristina An
Catherine Wilson
Alaa Hamed
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2022016019A publication Critical patent/MX2022016019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022016019A 2020-06-14 2021-06-11 Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio. MX2022016019A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063038857P 2020-06-14 2020-06-14
US202063076037P 2020-09-09 2020-09-09
US202163147629P 2021-02-09 2021-02-09
US202163157490P 2021-03-05 2021-03-05
PCT/US2021/037111 WO2021257409A1 (en) 2020-06-14 2021-06-11 Compositions and methods for treating late-onset pompe disease

Publications (1)

Publication Number Publication Date
MX2022016019A true MX2022016019A (es) 2023-04-10

Family

ID=76797137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016019A MX2022016019A (es) 2020-06-14 2021-06-11 Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio.

Country Status (13)

Country Link
US (2) US12533396B2 (enExample)
EP (1) EP4164678A1 (enExample)
JP (2) JP2023530112A (enExample)
KR (1) KR20230025874A (enExample)
CN (1) CN115916245A (enExample)
AU (1) AU2021293021A1 (enExample)
BR (1) BR112022025314A2 (enExample)
CA (1) CA3182409A1 (enExample)
IL (1) IL299015A (enExample)
MX (1) MX2022016019A (enExample)
TW (1) TW202214302A (enExample)
WO (1) WO2021257409A1 (enExample)
ZA (1) ZA202300544B (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
EP3608330B1 (en) * 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
EP4100120A1 (en) 2020-02-08 2022-12-14 Genzyme Corporation Compositions and methods for treating pompe disease

Also Published As

Publication number Publication date
WO2021257409A1 (en) 2021-12-23
US12533396B2 (en) 2026-01-27
US20230256062A1 (en) 2023-08-17
EP4164678A1 (en) 2023-04-19
JP2026117025A (ja) 2026-07-14
IL299015A (en) 2023-02-01
KR20230025874A (ko) 2023-02-23
BR112022025314A2 (pt) 2023-01-03
AU2021293021A1 (en) 2023-02-23
TW202214302A (zh) 2022-04-16
JP2023530112A (ja) 2023-07-13
CA3182409A1 (en) 2021-12-23
CN115916245A (zh) 2023-04-04
US20260216302A1 (en) 2026-07-30
ZA202300544B (en) 2026-02-25

Similar Documents

Publication Publication Date Title
MX2024005839A (es) Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos.
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
CR20200140A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
BR112022021963A2 (pt) Inibidores macrocíclicos de peptidilarginina desiminases
ZA202301784B (en) Crf2 receptor agonists and their use in therapy
MX2022001678A (es) Derivados amidas hibridas de anfotericina b.
PH12022550124A1 (en) Enzyme inhibitors
MX2024002131A (es) Inhibidores de la 17-beta-hidroxisteroide deshidrogenasa tipo 13 y metodos de uso de los mismos.
MX2021000016A (es) Formulaciones de factor de crecimiento de fibroblastos (fgf-21).
ZA202209925B (en) Compositions and methods for treating pompe disease
PH12022550512A1 (en) Liquid compositions comprising a levodopa amino acid conjugate and uses thereof
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
MX2025005223A (es) Agonistas del estimulador de genes de interferon (sting)
MX2025008424A (es) Formulacion de lanifibranor
EP4595996A3 (en) Treatment of lupus nephritis
ZA202202863B (en) Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions
MX2023005371A (es) Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso.
MX2022008336A (es) Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21).
PH12022553031A1 (en) Akt3 modulators
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
MX2024001889A (es) Compuestos deuterados.
MX2025003004A (es) Formas farmaceuticas de un inhibidor de cd73
ZA202300544B (en) Compositions and methods for treating late-onset pompe disease